Neurology Clinical Trials Market: Global Industry Analysis and Forecast (2021-2029) Trends, Statistics, Dynamics, Segmentation by Phase, Study Design, Indication, and Region

Neurology Clinical Trials Market size was valued at USD 5.2 Bn. in 2021 and the total Neurology Clinical Trials revenue is expected to grow by 6.5 % from 2022 to 2029, reaching nearly USD 8.6 Bn.

Neurology Clinical Trials Market Overview:

Neurological diseases are a leading cause of death in the elderly. People suffering from dementia, for example, are likely to have one or more chronic health conditions. Growing neurological disorders are boosting the market. MMR analyzed that the Neurological disorders were 28% in the year 2020 there was a growth in the neurologiocal disorders of about 9% and it was 37% in the year 2021. This is driving the neurological clinical trials market. One of the major contributors to the global disease burden has been identified as the rise in neurological illnesses. Cerebrovascular disease, Alzheimer's disease, other dementias, migraine, epilepsy, tetanus, meningitis, Parkinson's disease, multiple sclerosis, and poliomyelitis are just a few of the 1,000 neural system ailments. According to the Alzheimer Europe 2021 study, the number of dementia patients in Germany in 2019 was estimated to be 1,589,170, with this figure expected to rise to 2,749,190 by 2050. Dementia will affect 4.45% of the total population in 2050, up from 2.91% in 2019. The industry will benefit as the number of people suffering from dementia increases in the forecast years. As a result, the European and Western Pacific populations account for a sizable proportion of the population suffering from neurological illnesses. Neurostimulation devices are being used to treat a variety of disorders. As a result, neurostimulation devices are expected to be the most profitable medical equipment. Aside from the rising prevalence of neurological diseases, the neurology clinical trials market is also being driven by the robust product pipelines of the major players. Neurology Clinical Trials MarketTo know about the Research Methodology :- Request Free Sample Report Competitive Landscape: The Neurology Clinical Trials Market is highly competitive. Major market players presently dominate the industry in terms of market share. Supernus Pharmaceuticals, Inc. (US), Adamas Pharmaceuticals (US), Eli Lilly and Company (US), Aurora Health Care (US), and AbbVie Inc. (US) are among the leading market players. These industry participants were discovered to have a diverse product pipeline for neurological illnesses. The industry's top players are in the process of releasing improved products to enhance treatment efficiency, hence acquiring a larger market share. The Supernus Pharmaceuticals, Inc. used the strategy to become the leading players in the market they focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, on October 25, 2022, they launched their new products. Their diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. Additionally, the company is developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), is a company dedicated to developing and delivering medicines that improve the lives of people suffering from neurological diseases. They launched their new products on March 29, 2021, and published an article titled "Amantadine ER (Gocovri®) significantly increases ON time without any dyskinesia: Pooled analyses from pivotal studies in Parkinson's disease" in the peer-reviewed journal Frontiers in Neurology. GOCOVRI® (amantadine) extended-release capsules are the first and only medicine approved to treat dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, as well as to treat OFF episodes in PD patients receiving levodopa/carbidopa. The report not only represents global players but also local market holdings in each country. This report provides a comprehensive and insightful industry outlook based on the market structure by country, with market holdings by market leaders, market followers, and local players. The report covered the market's mergers and acquisitions, strategic alliances, joint ventures, and partnerships by region, investment, and strategic intent. Neurology Clinical Trials Market 1

Neurology Clinical Trials Market Dynamics:

Neurology Clinical Trials Market Drivers High Incidence of nerve injuries The growing frequency of neurological illnesses, as well as the huge number of nerve injuries, creates a strong need for a neurology clinical trials market. Globally, the geriatric population is also growing. The large geriatric population base, as well as the widespread frequency and incidence of nerve-related disorders among them, drives the neurological clinical trials market growth. Market participants and researchers are increasingly focused on advancing neurostimulation and neuromodulation technologies such as next-generation neurostimulation devices, collaborations among companies to launch advanced products, and the incoming latest technologies, which are driving the market growth. Government funding in neurological illness research drives the market's growth rate even higher. Neurology Clinical Trials Market 2Government support and initiatives With multiple government efforts and approvals to perform clinical studies of neurology, the central nervous cell treatment category is expected to grow at the quickest CAGR. According to the Organization for Economic Cooperation and Development (OECD), Denmark's average per capita healthcare spending in 2020 was around USD 5,600 Bn. As the number of people suffering from dementia is expected to increase in the forecast period, the neurology clinical trials market is likely to grow. A large number of research institutes, universities, and businesses from Europe, the United States, and Canada are also undertaking clinical studies for the use of stem cell-based therapeutics in nerve repair and regeneration. These countries are considered to have strong government support, a well-developed healthcare system, and a worldwide presence. As a result of the aforementioned factors, the category is expected to grow substantially during the forecast period.

Neurology Clinical Trials Market Restraints

Complications and risks are hampering the market CNS drugs and injections have a number of side effects, ranging from depersonalization and Inability to sleep, Increased blood pressure, and nerve damage, which hampers their use in the forecast years. Studies suggest that corticosteroid injections can lead to severe complications, such as skin discoloration, infections, and allergic reactions that may cause adverse health impacts. Additionally, these injections are prohibitively expensive, resulting in limited acceptance among ailing patients, further hampering neurology clinical trials market growth. Neurology Clinical Trials Market Opportunity Emerging economies to support the market With their large population bases, growing incidences of neurological illnesses, and improved healthcare infrastructure and spending, emerging economies such as India, China, and Brazil offer attractive market opportunities. The new technologies of stem cell treatment also present several prospects for neurology clinical trials market growth, with multiple stem cell therapy research now being conducted for nerve repair and regeneration reasons. Neurological research efforts have prolonged and continue to increase in recent years. For Instance, Medtronic acquired CE clearance for the InterStim Micro neurostimulator and InterStim SureScan MRI leads, allowing them to be sold commercially and used in clinical trials in Europe. InterStim Micro, the market's smallest rechargeable device for sacral neuromodulation (SNM) therapy, is used to treat overactive bladder (OAB), faecal incontinence (FI), and non-obstructive urine retention. When utilized with the InterStim Micro or the recharge-free InterStim II, the InterStim SureScan MRI leads give full-body 1.5 and 3 Tesla MRI-conditional images.

Neurology Clinical Trials Market Segment Analysis:

Based on Phase, In 2021, the phase II clinical trials segment dominated the neurology clinical trials market, accounting for 38.7% of total revenue. This is large because neurological disorders are extremely rare and no specific treatment is available. The vast majority of trials are in phase II or phase III. A total of 8,305 CNS trials were conducted between 2005 and 2021, with 609 trials taking place in 2020. During the forecast period, Phase III is expected to grow the fastest. This increase could be attributed to the fact that phase III clinical trials are the most expensive and involve a large number of participants. Phase III also necessitates a larger number of patients and, in many cases, a longer treatment period. The average cost of a phase III central nervous system clinical trial is USD 19.5 billion. From 1999 to 2020, a total of 12,092 CNS trials were conducted, with 629 trials taking place in 2020. Neurology Clinical Trials Market 3Based on the Study Design, The interventional segment led the market for neurology clinical trials market, accounting for the largest revenue share of 82.2% in 2021. It is one of the most common methods for carrying out a clinical experiment. The majority of studies were related to drugs or biologics, followed by behavioral, clinical procedure, and device intervention studies, accounting for 79.5% of all registered studies. The observational segment is expected to grow significantly during the forecast period. Observational studies are routinely used to evaluate treatment effects in a variety of situations, such as post-marketing drug safety evaluations or when clinical trials are not feasible. In observational studies, the prevalence of key prognostic factors associated with both treatment and outcome frequently differs between treatment groups. Neurology Clinical Trials Market 4Based on the Indication, The Huntington's disease segment is expected to grow at the fastest rate of 7.5% during the forecast period. This is largely due to increased R&D investment and the disease's widespread prevalence around the world. The EudraCT protocol is used in 40,635 clinical trials listed in the EU Clinical Trials Register, with 6631 of those involving children under the age of 18. Egypt, the Arab world's most populous country, has the highest prevalence of Huntington's disease; however, the country of 100 million people is underserved in Huntington's disease research. Huntington's disease affects 2.7 per 100,000 people worldwide and 10 per 100,000 in Europe, according to a new report. However, the disease affects 21 Egyptians out of every 100,000, or approximately 21,000 people. This figure is double the prevalence of Huntington's disease in Europe and 11 times higher than the national average. The countries with the highest prevalence of Huntington's disease are Ireland (10.8 per 100,000), Norway (6.8), Italy (6.38), Australia (6.3), Denmark (5.8), the United Kingdom (5.4), Slovenia (5.2), and Sweden (4.7). Neurology Clinical Trials Market 5

Neurology Clinical Trials Market Regional Insights:

North American region dominated the market with 45% of the market share in 2021. The United States is expected to have the largest market share. Factors such as high treatment awareness among the target population across the country, healthcare infrastructure, improved reimbursement policies, and increased business partnerships between pharmaceutical companies and contract research organizations are boosting the neurology clinical trials market in this region forward. According to a March 2021 report titled 'Alzheimer's Disease Facts and Figures,' this number is expected to rise to nearly 13.2 million by 2050. Moreover, according to Centers for Disease Control and Prevention (CDC) data updated in April 2022, someone in the United States has a stroke every 40 seconds. The prevalence of neurological disorders such as Alzheimer's, stroke, and others are expected to drive the market demand for new therapeutics. As a result, it is poised to drive the growth of the neurology clinical trials market under consideration. Neurology Clinical Trials Market 6Moreover, stroke is a leading cause of serious long-term disability and reduces mobility in more than half of stroke survivors 65 and older in the United States, according to the Centers for Disease Control and Prevention (CDC) in 2020. The geriatric population is one of the key factors driving neurology clinical trials market growth in this country, as the older population is more likely to contract this disease. As a result of the aforementioned factors, the North American region is expected to grow rapidly during the forecast period, fueling the growth of the neurology clinical trials market. The market for neurology clinical trials in the Middle East and Africa is expected to grow at the fastest rate of 8.5% during the forecast period. The Sub-Saharan Africa region is plagued by neurological, psychiatric, developmental, and substance use disorders caused or exacerbated by a lack of adequate nutrition and infectious disease, despite the fact that disorders associated with increased longevity, such as stroke, are on the rise. Major depressive disorders and post-traumatic stress disorder are serious issues in the Middle East and North Africa due to the conflict-torn environment.

Neurology Clinical Trials Market Scope: Inquiry Before Buying

Neurology Clinical Trials Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2029
Historical Data: 2017 to 2021 Market Size in 2021: US$ 5.2 Bn.
Forecast Period 2022 to 2029 CAGR: 6.5% Market Size in 2029: US$ 8.6 Bn.
Segments Covered: by Phase • Phase I • Phase II • Phase III • Phase IV
by Study Design • Interventional • Observational • Expanded Access
by Indication • Huntington's Disease • Epilepsy • Parkinson's Disease (PD) • Stroke • Traumatic Brain Injury (TBI) • Amyotrophic Lateral Sclerosis (ALS) • Muscle regeneration • Others

Neurology Clinical Trials Market by Region

• North America • Europe • Asia Pacific • South America • Middle East and Africa

Neurology Clinical Trials Market Key Players

• Supernus Pharmaceuticals, Inc. (US) • Adamas Pharmaceuticals (US) • Eli Lilly and Company (US) • Aurora Health Care (US) • AbbVie Inc. (US) • Medtronic (US) • Zydus Group (India) • Athira Pharma, Inc. (US) • Annovis Bio (US) • Biogen (US) • Merck & Co., Inc. (US) • IQVIA (US) • Covance (US) • Medpace (US) • Charles River Laboratories (US) • SyneousHealth (US) • AstraZeneca (UK) • GlaxoSmithKline plc (UK) • Teva Pharmaceutical Industries Ltd. (Israel) • Sanofi (France) • Novartis AG (Switzerland) • Eisai Co., Ltd. (Japan) • Icon Plc (Ireland) Frequently Asked Questions: 1] What segments are covered in the Global Neurology Clinical Trials Market report? Ans. The segments covered in the Neurology Clinical Trials Market report are based on Phase, Study Design, Indication, and Region. 2] Which region is expected to hold the highest share in the Global Neurology Clinical Trials Market? Ans. The North America region is expected to hold the highest share of the Neurology Clinical Trials Market. 3] What is the market size of the Global Neurology Clinical Trials Market by 2029? Ans. The market size of the Neurology Clinical Trials Market by 2029 is expected to reach US$ 8.6 Bn. 4] What is the forecast period for the Global Neurology Clinical Trials Market? Ans. The forecast period for the Neurology Clinical Trials Market is 2021-2029. 5] What was the market size of the Global Neurology Clinical Trials Market in 2021? Ans. The market size of the Neurology Clinical Trials Market in 2021 was valued at US$ 5.2 Bn.
1. Global Neurology Clinical Trials Market Size: Research Methodology 2. Global Neurology Clinical Trials Market Size: Executive Summary 2.1. Market Overview and Definitions 2.1.1. Introduction to Global Neurology Clinical Trials Market Size 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Neurology Clinical Trials Market Size: Competitive Analysis 3.1. MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2. Consolidation in the Market 3.2.1 M&A by region 3.3. Key Developments by Companies 3.4. Market Drivers 3.5. Market Restraints 3.6. Market Opportunities 3.7. Market Challenges 3.8. Market Dynamics 3.9. PORTERS Five Forces Analysis 3.10. PESTLE 3.11. Regulatory Landscape by region • North America • Europe • Asia Pacific • Middle East and Africa • South America 3.12. COVID-19 Impact 4. Global Neurology Clinical Trials Market Size Segmentation 4.1. Global Neurology Clinical Trials Market Size, by Phase (2021-2029) • Phase I • Phase II • Phase III • Phase IV 4.2. Global Neurology Clinical Trials Market Size, by Study Design (2021-2029) • Interventional • Observational • Expanded Access 4.3. Global Neurology Clinical Trials Market Size, by Indication (2021-2029) • Huntington's Disease • Epilepsy • Parkinson's Disease (PD) • Stroke • Traumatic Brain Injury (TBI) • Amyotrophic Lateral Sclerosis (ALS) • Muscle regeneration • Others 5. North America Neurology Clinical Trials Market (2021-2029) 5.1. North America Neurology Clinical Trials Market Size, by Phase (2021-2029) • Phase I • Phase II • Phase III • Phase IV 5.2. North America Neurology Clinical Trials Market Size, by Study Design (2021-2029) • Interventional • Observational • Expanded Access 5.3. North America Neurology Clinical Trials Market Size, by Indication (2021-2029) • Huntington's Disease • Epilepsy • Parkinson's Disease (PD) • Stroke • Traumatic Brain Injury (TBI) • Amyotrophic Lateral Sclerosis (ALS) • Muscle regeneration • Others 5.4. North America Semiconductor Memory Market, by Country (2021-2029) • United States • Canada • Mexico 6. European Neurology Clinical Trials Market (2021-2029) 6.1. European Neurology Clinical Trials Market, by Phase (2021-2029) 6.2. European Neurology Clinical Trials Market, by Study Design (2021-2029) 6.3. European Neurology Clinical Trials Market, by Indication (2021-2029) 6.4. European Neurology Clinical Trials Market, by Country (2021-2029) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Neurology Clinical Trials Market (2021-2029) 7.1. Asia Pacific Neurology Clinical Trials Market, by Phase (2021-2029) 7.2. Asia Pacific Neurology Clinical Trials Market, by Study Design (2021-2029) 7.3. Asia Pacific Neurology Clinical Trials Market, by Indication (2021-2029) 7.4. Asia Pacific Neurology Clinical Trials Market, by Country (2021-2029) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. Middle East and Africa Neurology Clinical Trials Market (2021-2029) 8.1. Middle East and Africa Neurology Clinical Trials Market, by Phase (2021-2029) 8.2. Middle East and Africa Neurology Clinical Trials Market, by Study Design (2021-2029) 8.3. Middle East and Africa Neurology Clinical Trials Market, by Indication (2021-2029) 8.4. Middle East and Africa Neurology Clinical Trials Market, by Country (2021-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Neurology Clinical Trials Market (2021-2029) 9.1. South America Neurology Clinical Trials Market, by Phase (2021-2029) 9.2. South America Neurology Clinical Trials Market, by Study Design (2021-2029) 9.3. South America Neurology Clinical Trials Market, by Indication (2021-2029) 9.4. South America Neurology Clinical Trials Market, by Country (2021-2029) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1. Supernus Pharmaceuticals, Inc. (US) 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. Adamas Pharmaceuticals (US) 10.3. Eli Lilly and Company (US) 10.4. Aurora Health Care (US) 10.5. AbbVie Inc. (US) 10.6. Medtronic (US) 10.7. Zydus Group (India) 10.8. Athira Pharma, Inc. (US) 10.9. Annovis Bio (US) 10.10. Biogen (US) 10.11. Merck & Co., Inc. (US) 10.12. IQVIA (US) 10.13. Covance (US) 10.14. Medpace (US) 10.15. Charles River Laboratories (US) 10.16. SyneousHealth (US) 10.17. AstraZeneca (UK) 10.18. GlaxoSmithKline plc (UK) 10.19. Teva Pharmaceutical Industries Ltd. (Israel) 10.20. Sanofi (France) 10.21. Novartis AG (Switzerland) 10.22. Eisai Co., Ltd. (Japan) 10.23. Icon Plc (Ireland)

About This Report

Report ID 171139
Category Healthcare
Published Date Jan 2023
Updated Date
Contact Us